According to Zacks, "Ligand delivered better-than-expected second-quarter results with the company beating both top- and bottom-line estimates. Ligand's Captisol formulation technology has resulted in partnerships with several leading health care companies like Novartis, Amgen and Pfizer among others that provide the company with funds in the form of milestone and royalty payments.